STOCK TITAN

Iterum Therapeutics Plc - ITRM STOCK NEWS

Welcome to our dedicated news page for Iterum Therapeutics Plc (Ticker: ITRM), a resource for investors and traders seeking the latest updates and insights on Iterum Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Iterum Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Iterum Therapeutics Plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.57%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
earnings
Iterum Therapeutics Plc

Nasdaq:ITRM

ITRM Rankings

ITRM Stock Data

20.69M
11.99M
1.85%
9.2%
8.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About ITRM

iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.